Low-dose IFN of no benefit in high-risk melanoma

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2004

Schlagwörter:	Melanoma Overall Survival Risk Melanoma Adjuvant Interferon Pittsburgh Cancer Institute

Anmerkung:	© Adis International Ltd 2004

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1421(2004), 1 vom: Jan., Seite 18-18
Übergeordnetes Werk:	volume:1421 ; year:2004 ; number:1 ; month:01 ; pages:18-18

Links:	Volltext

DOI / URN:	10.2165/00128413-200414210-00043

Katalog-ID:	SPR035177063

Internformat


LEADER	01000caa a22002652 4500
001	SPR035177063
003	DE-627
005	20230519235324.0
007	cr uuu---uuuuu
008	201007s2004 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200414210-00043 \|2 doi
035			\|a (DE-627)SPR035177063
035			\|a (SPR)00128413-200414210-00043-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Low-dose IFN of no benefit in high-risk melanoma
264		1	\|c 2004
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2004
650		4	\|a Melanoma \|7 (dpeaa)DE-He213
650		4	\|a Overall Survival \|7 (dpeaa)DE-He213
650		4	\|a Risk Melanoma \|7 (dpeaa)DE-He213
650		4	\|a Adjuvant Interferon \|7 (dpeaa)DE-He213
650		4	\|a Pittsburgh Cancer Institute \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1421(2004), 1 vom: Jan., Seite 18-18 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1421 \|g year:2004 \|g number:1 \|g month:01 \|g pages:18-18
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200414210-00043 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_206
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4305
951			\|a AR
952			\|d 1421 \|j 2004 \|e 1 \|c 01 \|h 18-18

Indexfelder

matchkey_str	article:22306056:2004----::odsinfoeeiihg
hierarchy_sort_str	2004
publishDate	2004
allfields	10.2165/00128413-200414210-00043 doi (DE-627)SPR035177063 (SPR)00128413-200414210-00043-e DE-627 ger DE-627 rakwb eng Low-dose IFN of no benefit in high-risk melanoma 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2004 Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1421(2004), 1 vom: Jan., Seite 18-18 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1421 year:2004 number:1 month:01 pages:18-18 https://dx.doi.org/10.2165/00128413-200414210-00043 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1421 2004 1 01 18-18
spelling	10.2165/00128413-200414210-00043 doi (DE-627)SPR035177063 (SPR)00128413-200414210-00043-e DE-627 ger DE-627 rakwb eng Low-dose IFN of no benefit in high-risk melanoma 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2004 Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1421(2004), 1 vom: Jan., Seite 18-18 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1421 year:2004 number:1 month:01 pages:18-18 https://dx.doi.org/10.2165/00128413-200414210-00043 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1421 2004 1 01 18-18
allfields_unstemmed	10.2165/00128413-200414210-00043 doi (DE-627)SPR035177063 (SPR)00128413-200414210-00043-e DE-627 ger DE-627 rakwb eng Low-dose IFN of no benefit in high-risk melanoma 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2004 Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1421(2004), 1 vom: Jan., Seite 18-18 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1421 year:2004 number:1 month:01 pages:18-18 https://dx.doi.org/10.2165/00128413-200414210-00043 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1421 2004 1 01 18-18
allfieldsGer	10.2165/00128413-200414210-00043 doi (DE-627)SPR035177063 (SPR)00128413-200414210-00043-e DE-627 ger DE-627 rakwb eng Low-dose IFN of no benefit in high-risk melanoma 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2004 Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1421(2004), 1 vom: Jan., Seite 18-18 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1421 year:2004 number:1 month:01 pages:18-18 https://dx.doi.org/10.2165/00128413-200414210-00043 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1421 2004 1 01 18-18
allfieldsSound	10.2165/00128413-200414210-00043 doi (DE-627)SPR035177063 (SPR)00128413-200414210-00043-e DE-627 ger DE-627 rakwb eng Low-dose IFN of no benefit in high-risk melanoma 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2004 Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1421(2004), 1 vom: Jan., Seite 18-18 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1421 year:2004 number:1 month:01 pages:18-18 https://dx.doi.org/10.2165/00128413-200414210-00043 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1421 2004 1 01 18-18
language	English
source	Enthalten in Inpharma weekly 1421(2004), 1 vom: Jan., Seite 18-18 volume:1421 year:2004 number:1 month:01 pages:18-18
sourceStr	Enthalten in Inpharma weekly 1421(2004), 1 vom: Jan., Seite 18-18 volume:1421 year:2004 number:1 month:01 pages:18-18
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Melanoma Overall Survival Risk Melanoma Adjuvant Interferon Pittsburgh Cancer Institute
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2004-01-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR035177063
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035177063</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519235324.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200414210-00043</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035177063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200414210-00043-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Low-dose IFN of no benefit in high-risk melanoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2004</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Melanoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk Melanoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvant Interferon</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pittsburgh Cancer Institute</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1421(2004), 1 vom: Jan., Seite 18-18</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1421</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:18-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200414210-00043</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1421</subfield><subfield code="j">2004</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">18-18</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Low-dose IFN of no benefit in high-risk melanoma Melanoma (dpeaa)DE-He213 Overall Survival (dpeaa)DE-He213 Risk Melanoma (dpeaa)DE-He213 Adjuvant Interferon (dpeaa)DE-He213 Pittsburgh Cancer Institute (dpeaa)DE-He213
topic	misc Melanoma misc Overall Survival misc Risk Melanoma misc Adjuvant Interferon misc Pittsburgh Cancer Institute
spellingShingle	misc Melanoma misc Overall Survival misc Risk Melanoma misc Adjuvant Interferon misc Pittsburgh Cancer Institute Low-dose IFN of no benefit in high-risk melanoma
topic_unstemmed	misc Melanoma misc Overall Survival misc Risk Melanoma misc Adjuvant Interferon misc Pittsburgh Cancer Institute
topic_browse	misc Melanoma misc Overall Survival misc Risk Melanoma misc Adjuvant Interferon misc Pittsburgh Cancer Institute
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Low-dose IFN of no benefit in high-risk melanoma
ctrlnum	(DE-627)SPR035177063 (SPR)00128413-200414210-00043-e
title_full	Low-dose IFN of no benefit in high-risk melanoma
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2004
contenttype_str_mv	txt
container_start_page	18
container_volume	1421
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200414210-00043
title_sort	low-dose ifn of no benefit in high-risk melanoma
title_auth	Low-dose IFN of no benefit in high-risk melanoma
abstract	© Adis International Ltd 2004
abstractGer	© Adis International Ltd 2004
abstract_unstemmed	© Adis International Ltd 2004
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305
container_issue	1
title_short	Low-dose IFN of no benefit in high-risk melanoma
url	https://dx.doi.org/10.2165/00128413-200414210-00043
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200414210-00043
up_date	2024-07-03T13:48:23.069Z
_version_	1803565927572176897
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035177063</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519235324.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200414210-00043</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035177063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200414210-00043-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Low-dose IFN of no benefit in high-risk melanoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2004</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Melanoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk Melanoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvant Interferon</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pittsburgh Cancer Institute</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1421(2004), 1 vom: Jan., Seite 18-18</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1421</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:18-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200414210-00043</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1421</subfield><subfield code="j">2004</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">18-18</subfield></datafield></record></collection>
score	7.401434

Nicht das Richtige dabei?

Schreiben Sie uns!

Low-dose IFN of no benefit in high-risk melanoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?